Libevitug Approved in China as First-in-Class Treatment for Hepatitis D
PR Newswire —
BEIJING, Jan. 27, 2026 /PRNewswire/ -- Huahui Health announced that China National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for the treatment of chronic hepatitis D virus infection in adults with or without compensated cirrhosis....